This approval makes Eli Lillys oral GLP-1 receptor agonist, to be marketed as Foundayo, the second GLP-1 drug for weight loss available in pill form, after Wegovy, which gained approval in December 2025
Avoid injecting into: Areas of broken, irritated, or sunburned skin Sites with bruising, swelling, or active infection Scar tissue or stretch marks , which may impair absorption Moles, warts, or skin lesions The area directly around the navel (within 5 cm) Waistbands or areas subject to friction from clothing Any site showing signs of lipohypertrophy (hardened, lumpy, or thickened skin) Mild injection site reactions such as temporary redness, minor swelling, or slight itching are relatively common with subcutaneous injectables and usually resolve within a few hours to days
These medications can be filled at the pharmacy of your choice
Quieting "Food Noise": How GLP-1s and Mindfulness Rewire the Default Mode Network (DMN) and Reward Circuits